Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.
Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Brüning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R. Ji Y, et al. Among authors: dixon jm. Cancer Res. 2008 Jul 15;68(14):5997-6005. doi: 10.1158/0008-5472.CAN-08-0043. Cancer Res. 2008. PMID: 18632656 Free PMC article.
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN. Wang L, et al. Among authors: dixon jm. Cancer Res. 2010 Jan 1;70(1):319-28. doi: 10.1158/0008-5472.CAN-09-3224. Cancer Res. 2010. PMID: 20048079 Free PMC article.
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, Ghazoui Z, Rani A, Osin P, Nerurkar A, Renshaw L, Larionov A, Miller WR, Dixon JM, Reis-Filho JS, Dunbier AK, Martin LA, Dowsett M. López-Knowles E, et al. Among authors: dixon jm. Breast Cancer Res. 2015 Mar 11;17(1):35. doi: 10.1186/s13058-015-0532-0. Breast Cancer Res. 2015. PMID: 25888249 Free PMC article.
Neoadjuvant endocrine therapy models.
Murray J, Miller WR, Dixon JM. Murray J, et al. Among authors: dixon jm. Methods Mol Med. 2006;120:489-502. doi: 10.1385/1-59259-969-9:489. Methods Mol Med. 2006. PMID: 16491621
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M. Mackay A, et al. Among authors: dixon jm. Breast Cancer Res. 2007;9(3):R37. doi: 10.1186/bcr1732. Breast Cancer Res. 2007. PMID: 17555561 Free PMC article. Clinical Trial.
Increase in response rate by prolonged treatment with neoadjuvant letrozole.
Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB, Miller WR. Dixon JM, et al. Breast Cancer Res Treat. 2009 Jan;113(1):145-51. doi: 10.1007/s10549-008-9915-6. Epub 2008 Feb 9. Breast Cancer Res Treat. 2009. PMID: 18264759 Clinical Trial.
549 results